Clinical Validation of an Alternative Specimen Collection Kit for SARS-CoV-2 Testing at Fox Chase Cancer Center

Don A. Baldwin, Cheyenne R. Gigli, Tim Kwok, Sharon Connelly, James L. Helstrom, Barbara Ebersole, Eric A. Ross, Michael Araten, Joel Glickman, Robert Glickman, Eric M. Horwitz

Research output: Contribution to journalArticlepeer-review


Background: Supply chain disruptions during the COVID-19 pandemic have affected the availability of components for specimen collection kits to detect SARS-CoV-2. Plastic injection molding offers a rapid and cheap method for mass production of swabs for upper respiratory tract sampling. Local production of virus transport medium increases flexibility to assemble sample collection kits if the medium provides appropriate stability for SARS-CoV-2 detection. Methods: A locally produced virus transport medium and a novel injection molded plastic swab were validated for SARS-CoV-2 detection by reverse-transcription quantitative polymerase chain reaction. Both components were compared to standard counterparts using viral reference material and representative patient samples. Results: Clinical testing showed no significant differences between molded and flocked swabs. Commercial and in-house virus transport media provided stable test results for over 40 days of specimen storage and showed no differences in test results using patient samples. Conclusions: This collection kit provides new supply chain options for SARS-CoV-2 testing.

Original languageEnglish
Article number3fc1f5fe.2008dbc6
JournalJournal of Biomolecular Techniques
Issue number3
StatePublished - Sep 15 2022


  • COVID-19
  • COVID-19 Testing
  • Culture Media
  • Humans
  • Nasopharynx/chemistry
  • Neoplasms
  • Pandemics
  • RNA, Viral
  • SARS-CoV-2
  • Specimen Handling/methods


Dive into the research topics of 'Clinical Validation of an Alternative Specimen Collection Kit for SARS-CoV-2 Testing at Fox Chase Cancer Center'. Together they form a unique fingerprint.

Cite this